The investment seeks to provide investment results that, before fees and expenses, correspond generally to the price and yield performance of the FLAGLSX-Forensic Accounting Long-Short Index. The investment seeks to provide investment results that, before fees and expenses, correspond generally to the price and yield performance of the FLAGLSX-Forensic Accounting Long-Short Index.
SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted...
SAN DIEGO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted...
SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted...
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted...
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of...
SAN DIEGO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of...
SAN DIEGO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted...
SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted...
SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of...
SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0248 | 3.28389830508 | 0.7552 | 0.8 | 0.58 | 651759 | 0.65511514 | CS |
4 | -0.45 | -36.5853658537 | 1.23 | 1.49 | 0.58 | 1129526 | 0.99755277 | CS |
12 | -0.78 | -50 | 1.56 | 3.89 | 0.58 | 1801981 | 2.09686982 | CS |
26 | -0.89 | -53.2934131737 | 1.67 | 3.89 | 0.58 | 1024682 | 1.89250487 | CS |
52 | -7.73 | -90.8343125734 | 8.51 | 16.8 | 0.58 | 1141926 | 2.494439 | CS |
156 | -44.32 | -98.2705099778 | 45.1 | 50 | 0.58 | 842758 | 2.92426656 | CS |
260 | -44.32 | -98.2705099778 | 45.1 | 50 | 0.58 | 842758 | 2.92426656 | CS |
Symbol | Price | Vol. |
---|---|---|
SOXLDirexion Daily Semiconductor Bull 3X Shares | $ 27.02 (-0.48%) | 102.26M |
SPXSDirexion Daily S&P 500 Bear 3X Shares New | $ 5.82 (1.39%) | 81.08M |
TSLZT Rex 2X Inverse Tesla Daily Target ETF | $ 2.3017 (-2.26%) | 75.06M |
NVDQT Rex 2X Inverse NVIDIA Daily Target ETF | $ 3.565 (7.70%) | 70.47M |
SOXSDirexion Daily Semiconductor Bear 3X Shares New | $ 20.61 (0.73%) | 67.19M |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.